Ultrasound‐Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation
Advanced Science · 2025
DOI: 10.1002/advs.202503196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhili Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Institute of Ultrasound in Musculoskeletal Sports Medicine, The Affiliated Guangdong Second Provincial General Hospital of …. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Transfection, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Science and Technology Program.
Abstract (Originalsprache)
The lack of stem cells and difficulty in osteogenic differentiation are the primary challenges to treating bone defects. Stem cell gene therapy can efficiently replenish the number of stem cells and facilitate bone differentiation, but its security and efficacy remain challenging. The traditional ultrasound‐targeted microbubble destruction (UTMD) technology with extracellular cavitation for gene transfection is safe but inefficient. Consequently, gas vesicles extracted from Halobacterium NRC‐1 are used as carriers, incorporating nuclear localization signal, polyethyleneimine, and plasmid bone morphogenetic protein 2 (pBMP2). Then followed by internalization into bone marrow mesenchymal stem cells (BMSCs) to produce engineered BMSCs, which exhibit significant capacity of lysosome escape and nuclear targeting. The permeability of the nuclear membrane is substantially enhanced by low‐intensity pulsed ultrasound through intracellular cavitation, thereby increasing plasmid nuclear translocation efficiency and gene transfection efficiency by 284.7% and 131.6%, respectively, compared to conventional UTMD techniques. Besides, the expression of BMP2 is maintained for 21 days, promoting osteogenic differentiation of BMSCs and enhancing bone defect repair. In conclusion, this study provides a more secure, efficient, and regulated approach to BMSCs gene therapy for bone defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, Institute of Ultrasound in Musculoskeletal Sports Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 510317, China.
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, China.
ORCID-Profile: Hongmei Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangzhou Science and Technology Program
- Featured Clinical Technique of Guangzhou
- Talents' Plan Foundation of Guangdong Second Provincial General Hospital
Zitieren
APA
Xu, Z., Xin, H., Wang, Y., Xu, R., He, Y., Zhou, M., Yuan, Z., & Liu, H. (2025). Ultrasound‐Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation. Advanced Science. https://doi.org/10.1002/advs.202503196
Vancouver
Xu Z, Xin H, Wang Y, Xu R, He Y, Zhou M, et al. Ultrasound‐Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation. Advanced Science. 2025. doi:10.1002/advs.202503196
BibTeX
@article{Xu2025,
author = {Xu, Zhili and Xin, Huijuan and Wang, Yu and Xu, Renhao and He, Yanni and Zhou, Meijun and Yuan, Zhengqiang and Liu, Hongmei},
title = {Ultrasound‐Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503196}
}
EUVIMED